transporter proteins such as Pgp, MRP2, and OATP (Eloranta et al., 2005;
Klaassen and Slitt, 2005). When CYP3A4 induction occurs, induction of these
additional nonCYP drug disposition proteins is also possible. Therefore, any
coadministered drugs that are metabolized or otherwise processed by these
proteins could potentially be subject to increased clearance, and the potential
for decreased plasma levels and subtherapeutic concentrations at normal doses
must be considered as a possible consequence of PXR activation.
References
Araya Z, Wikvall K. 6alpha-hydroxylation of taurochenodeoxycholic acid and
lithocholic acid by CYP3A4 in human liver microsomes. Biochim Biophys Acta
1999;1438:47–54.
Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma
concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7–13.
Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M,
Ohlsson R, Postlind H, Blomquist P, Berkenstam A. Identification of a human
nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl
Acad Sci USA 1998;95:12208–12213.
Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP,
Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris
F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct ofin vitro
andin vivodrug–drug interaction studies: a PhRMA perspective. J Clin Pharmacol
2003;43:443–469.
Blumberg B, Sabbagh W, Juguilon H, Bolado J, van Meter CM, Jr, Ong ES, Evans RM.
SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev
1998;12:3195–3205.
Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, Eggertsen G,
Bjorkhem I, Diczfalusy U. Metabolism of 4 beta-hydroxycholesterol in humans.
J Biol Chem 2002;277:31534–31540.
Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C, Diczfalusy U.
Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans:
evidence for involvement of cytochrome p450 3A4. J Biol Chem 2001;276:38685–
38689.
Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based
inactivator of cytochrome P450 3A4. Life Sci 2000;67:3103–3112.
Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, Gervot L, Lesca P,
Domergue J, Joyeux H, Fourtanier G, Maurel P. Omeprazole and lansoprazole are
mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J
Pharmacol Exp Ther 1994;269:384–392.
Czerwinski M, Opdam P, Madan A, Carroll K, Mudra DR, Gan LL, Luo G, Parkinson
A. Analysis of CYP mRNA expression by branched DNA technology. Methods
Enzymol 2002;357:170–179.
566 TESTING DRUG CANDIDATES FOR CYP3A4 INDUCTION